Epigenetic Plasticity Linking Drug Resistance and Immune Evasion in Ovarian Cancer: Mechanisms and Therapeutic Opportunities

Background: Ovarian cancer remains difficult to control because of tumour heterogeneity, recurrent disease, therapeutic resistance, and an immunosuppressive tumour microenvironment. Epigenetic plasticity may connect these processes by enabling reversible transcriptional adaptation. This review examines how epigenetic mechanisms contribute to drug resistance and immune evasion in ovarian cancer and evaluates their therapeutic relevance. Methods: We conducted a narrative synthesis of evidence concerning DNA methylation, histone modifications, chromatin remodelling, and non-coding RNAs in ovarian cancer. Mechanistic findings were integrated with biomarker studies, preclinical therapeutic investigations, and clinical trials, while distinguishing ovarian cancer-specific evidence from observations extrapolated from other malignancies. Results: Epigenetic dysregulation influences DNA repair, homologous recombination, cancer stemness, epithelial–mesenchymal transition, apoptotic escape, metabolic adaptation, antigen presentation, interferon signalling, chemokine expression, immune checkpoints, and tumour–immune interactions. DNA methylation and H3K27me3-associated regulation provide some of the strongest ovarian cancer-specific mechanistic evidence linking epigenetic plasticity to platinum or PARP-inhibitor response and immune-cell recruitment. Non-coding RNAs and emerging histone modifications further regulate resistant and immune-evasive phenotypes, although much of this evidence remains preclinical. Early clinical studies of DNA-demethylating agents combined with platinum chemotherapy, immune checkpoint inhibitors, or cancer vaccines demonstrate biological activity in selected settings but have not established consistent or durable clinical benefit. Conclusions: Epigenetic plasticity represents a potentially targetable, context-dependent link between therapeutic resistance and immune evasion in ovarian cancer. Translation will require histotype-specific models, longitudinal epigenomic and immune profiling, predictive biomarkers, and biomarker-guided trials that account for target selectivity, treatment sequencing, toxicity, and effects on normal immune cells.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-17
DOI
https://doi.org/10.3390/cancers18223676
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Epigenetic Plasticity Linking Drug Resistance and Immune Evasion in Ovarian Cancer: Mechanisms and Therapeutic Opportunities

Rajdeep Chowdhury, Magdalena Plebanski, Apriliana E. R. Kartikasari, Suryachandra Kandi
2 links
Cancers
Epigenetics and DNA Methylation
article

Epigenetic Plasticity Linking Drug Resistance and Immune Evasion in Ovarian Cancer: Mechanisms and Therapeutic Opportunities

Rajdeep Chowdhury, Magdalena Plebanski, Apriliana E. R. Kartikasari, Suryachandra Kandi
article en

Abstract

Background: Ovarian cancer remains difficult to control because of tumour heterogeneity, recurrent disease, therapeutic resistance, and an immunosuppressive tumour microenvironment. Epigenetic plasticity may connect these processes by enabling reversible transcriptional adaptation. This review examines how epigenetic mechanisms contribute to drug resistance and immune evasion in ovarian cancer and evaluates their therapeutic relevance. Methods: We conducted a narrative synthesis of evidence concerning DNA methylation, histone modifications, chromatin remodelling, and non-coding RNAs in ovarian cancer. Mechanistic findings were integrated with biomarker studies, preclinical therapeutic investigations, and clinical trials, while distinguishing ovarian cancer-specific evidence from observations extrapolated from other malignancies. Results: Epigenetic dysregulation influences DNA repair, homologous recombination, cancer stemness, epithelial–mesenchymal transition, apoptotic escape, metabolic adaptation, antigen presentation, interferon signalling, chemokine expression, immune checkpoints, and tumour–immune interactions. DNA methylation and H3K27me3-associated regulation provide some of the strongest ovarian cancer-specific mechanistic evidence linking epigenetic plasticity to platinum or PARP-inhibitor response and immune-cell recruitment. Non-coding RNAs and emerging histone modifications further regulate resistant and immune-evasive phenotypes, although much of this evidence remains preclinical. Early clinical studies of DNA-demethylating agents combined with platinum chemotherapy, immune checkpoint inhibitors, or cancer vaccines demonstrate biological activity in selected settings but have not established consistent or durable clinical benefit. Conclusions: Epigenetic plasticity represents a potentially targetable, context-dependent link between therapeutic resistance and immune evasion in ovarian cancer. Translation will require histotype-specific models, longitudinal epigenomic and immune profiling, predictive biomarkers, and biomarker-guided trials that account for target selectivity, treatment sequencing, toxicity, and effects on normal immune cells.

CancersVol. 18(22)
Birla Institute of Technology and Science, Pilani (IN), RMIT University (AU)
RMIT University, Birla Institute of Technology and Science, Pilani
Good health and well-being
Epigenetics and DNA Methylation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon